GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.
You may also be interested in...
Walmsley Takes On Oncology: Can GSK Become A Power Player?
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.